Join to View Full Profile
4545 E Shea BlvdSte 175Phoenix, AZ 85028
Phone+1 480-314-1007
Fax+1 480-314-1003
Dr. Sivakumar is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Neurology, 1990 - 1993
University of Peradeniya FOMClass of 1987
Certifications & Licensure
AZ State Medical License 1997 - 2027
MD State Medical License 1993 - 1997
American Board of Psychiatry and Neurology Neurology- American Board of Psychiatry and Neurology Clinical Neurophysiology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Allscripts Professional EHR, Allscripts, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification Allscripts MyWay EHR, Allscripts, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Professional EHR, Allscripts, 2012, 2014, 2016-2017
Clinical Trials
- Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Start of enrollment: 2011 Sep 08
- Study of Eteplirsen in DMD Patients Start of enrollment: 2014 Nov 17
- Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy Start of enrollment: 2015 Jun 30
Publications & Presentations
PubMed
- A Phase 3 Trial of Brepocitinib in Dermatomyositis.Ruth Ann Vleugels, Julie J Paik, Iazsmin Bauer Ventura, Aaron R Mangold, Prateek C Gandiga
The New England Journal of Medicine. 2026-05-14 - Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).Barry J Byrne, Benedikt Schoser, Priya S Kishnani, Drago Bratkovic, Paula R Clemens
Journal of Neurology. 2025-02-17 - 37 citationsSafety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.Carlo Antozzi, Tuan Vu, Sindhu Ramchandren, Richard J Nowak, Constantine Farmakidis
The Lancet. Neurology. 2025-02-01
Journal Articles
- Exome sequencing identifies titin mutations causing hereditary myopathy with early respiratory failure (HMERF) in families of diverse ethnic originsToro C, Olive M, Dalakas M, Sivakumar K, Bilbao JM, Tyndel F, Vidal N, Farrero E, Sambuughin N, Goldfarb LG, BMC Neurol, 1/1/2013
- Autosomal recessive spastic ataxia of Charlevoix-Saguenay: compound heterozygotes for nonsense mutations of the SACS geneNarayanan V, Rice SG, Olfers SS, Sivakumar K, J Child Neurol, 1/1/2011
- Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affectPioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, Hepner A, Kaye R; Safety, Ann Neurol, 1/1/2010
Abstracts/Posters
- Assessment of Mortality in Sporadic Inclusion Body Myositis: A Delphi Panel TechniquePrice M, Barghout V, Benveniste O, Christopher-Stine L, Corbett A, de Visser M, Hilton-Jones D, Kissel JT, Lloyd T, Lundberg I, Mastaglia F, Mozaffar T, Needham M, Sch..., American Academy of Neurology 66th Annual Meeting, 4/1/2014
- Progress in inflammatory myopathiesSivakumar K, Srilankan Association of Neurologist, 11/1/2013
- Treatment of sporadic Inclusion Body Myositis with an anti-activin receptor IIB antibodyAmato A, Sivakumar K, Goyal N, David W, Barohn RJ, Salajegheh M, Laurent D, Praestgaard J, Trifilieff E, Trendelenburg A, Glass DJ, Roubenoff R, Tseng BS, Greenberg SA, MDA Conference, 1/1/2013
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
